Annexon, Inc.
ANNXNext catalyst
Tanruprubart
Guillain-Barre Syndrome
Get an email about ANNX's next catalysts
Track Annexon (ANNX) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 2 more upcoming events in our data (earnings, Phase 3 readout).See the timeline
3 upcoming, 0 past
ANNX Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-0.28 | FQ end Sep/2026 | Call: tbd
Tanruprubart Phase 3 Est. Readout
Primary completion for Tanruprubart trial (NCT07020819) in Guillain-Barre Syndrome
SourceVonaprument Phase 3 Est. Readout (ARCHER II)
Primary completion for Vonaprument trial (NCT06510816) in Geographic Atrophy
SourceMarket Overview
Stock performance and key metrics
Vonaprument
Geographic Atrophy
Tanruprubart
Guillain-Barre Syndrome
ANX005
Warm Autoimmune Hemolytic Anemia (wAIHA)
ANX007
Geographic Atrophy
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Vonaprument | Phase 3 | Geographic Atrophy | - | - |
Tanruprubart | Phase 3 | Guillain-Barre Syndrome | - | - |
ANX005 | Phase 3 | Warm Autoimmune Hemolytic Anemia (wAIHA) | - | - |
ANX007 | Phase 2 | Geographic Atrophy | - | - |
Geographic Atrophy
2 drugs in this indication
Guillain-Barre Syndrome
1 drug in this indication
Warm Autoimmune Hemolytic Anemia (wAIHA)
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Annexon, Inc.'s drug pipeline?→
CatalystAlert tracks 4 drug candidates in Annexon, Inc.'s (ANNX) pipeline across Phase 3, Phase 2. Its lead program is Tanruprubart (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Annexon, Inc.'s next FDA catalyst?→
Annexon, Inc.'s (ANNX) next tracked catalyst is a Phase 3 readout expected Q2 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ANNX biotech catalysts?→
Add ANNX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Annexon, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.